Compare FC & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FC | ALXO |
|---|---|---|
| Founded | 1983 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 231.6M | 205.9M |
| IPO Year | 1994 | 2020 |
| Metric | FC | ALXO |
|---|---|---|
| Price | $21.13 | $1.92 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $26.00 | $3.50 |
| AVG Volume (30 Days) | 107.0K | ★ 882.8K |
| Earning Date | 04-01-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.36 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $267,067,000.00 | N/A |
| Revenue This Year | $3.15 | N/A |
| Revenue Next Year | $4.04 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $11.16 | $0.51 |
| 52 Week High | $26.81 | $2.66 |
| Indicator | FC | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 52.04 | 47.02 |
| Support Level | $20.36 | $1.42 |
| Resistance Level | $24.13 | $2.31 |
| Average True Range (ATR) | 0.97 | 0.15 |
| MACD | 0.20 | -0.02 |
| Stochastic Oscillator | 89.19 | 10.91 |
Franklin Covey Co is a company focused on organizational performance improvement. It operates in the business segments of North America, International Direct Offices, International Licensees, Education Division. The company derives revenue from providing training and consulting services and through the sale of books, audio media, and other related products. It has a business presence in Australia, New Zealand, China, Japan, the United Kingdom, Ireland, and Other countries.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. It is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.